

HCL Technologies

HOLD

Cautious on ramp downs and discretionary spends

Summary

HCL Technologies (HCLT) reported 15.8% cc organic growth in FY23E led by market share gains. The company's Q4 IT services revenues was also healthy up 0.6% QoQ led by ramp of mega deals won. Going forward the company has guided FY24E revenue growth of 6-8% YoY and EBIT margins of 18-19% for FY24E. We expect the company to be at the lower end of the guidance mainly led by lower ACV growth (up 4.3% YoY vs 21% YoY in FY22). Further, we expect ramp downs in projects, delay in renewals and lower discretionary spend to further impact revenue growth. In addition, due to headwinds like wage hikes and lower ability to manage cost in uncertainty we have assumed margins at the lower end of guidance (18%). Consequently we have lowered our EPS estimates by 1.7% & 1.6% for FY23E & FY24E. Hence, we maintain our HOLD rating on the stock with a revised target price of Rs 1010 (16x PE on FY25E EPS).

Key Highlights and Investment Rationale

- Vendor consolidation & cost efficiency to drive growth: HCL Technologies is in a sweet spot to gain market share as cost efficiency deals are forte of the company. Further, winning of multiple mega deals, ramp up in large deals, lower impact of banking crisis (very miniscule) and vendor consolidation will drive revenue growth. However, poor outlook of tech sector, delay in decision making, lower discretionary spend in ER&D and weak product growth could act as a headwind to company's growth trajectory. Hence, we expect US\$ revenue CAGR of 7.6% over FY23-25E.
- Operating margins to remain range bound: The company has multiple levers like higher utilisation, pyramid utilisation and offshoring to drive margins. However, wage hike and lower revenues growth prompt us to keep margins in a narrow range of 18.1% and 18.3% in FY24E & FY25E, respectively.

TP Rs	1,010
CMP Rs	1,038
Potential upside/downside	e -3%
Previous Rating	HOLD

Price Performance (%)							
	-1m	-3m	-12m				
Absolute	(4.9)	(6.3)	(4.8)				
Rel to Sensex	(8.4)	(4.7)	(9.3)				

V/s Consensus		
EPS (Rs)	FY24E	FY25E
IDBI Capital	56.4	62.3
Consensus	61.0	68.3
% difference	(7.6)	(8.8)

Key Stock DataBloomberg/ReutersHCLT IN/ HCLT.BOSectorIT ServicesShares o/s (mn)2,714Market cap. (Rs mn)2,815,5633-m daily avg Trd value (Rs mn)95.952-week high / lowRs1,157 / 876Sensex / Nifty59,632 / 17,624

Shareholding Pattern (%)	
Promoters	60.7
FII	18.3
DII	15.1
Public	5.9

Financial snapshot

(Rs mn)

Year	FY21	FY22	FY23E	FY24E	FY25E
Revenue	753,790	856,510	1,014,560	1,096,587	1,198,167
Change (yoy, %)	7	14	18	8	9
EBITDA	207,750	205,300	226,280	245,328	269,805
Change (yoy, %)	24	-1	10	8	10
EBITDA Margin (%)	27.6	24.0	22.3	22.4	22.5
Adj. PAT	129,410	134,990	148,510	153,131	169,070
EPS (Rs)	47.7	49.7	54.7	56.4	62.3
Change (yoy, %)	18	4	10	3	10
PE(x)	22	21	19	18	17
Dividend Yield (%)	3	4	5	4	5
EV/EBITDA (x)	13	13	12	11	10
RoE (%)	23.3	22.2	23.3	22.9	24.1
RoCE (%)	26	24	26	27	28
Carrier IDDI Carrital Danamah					

Source: IDBI Capital Research;

Devang Bhatt

devang.bhatt@idbicapital.com +91-22-2217 1846

Dhawal Doshi

dhawal.doshi@idbicapital.com +91-22-2217 1841



Other Key Highlights

- Overall revenue in CC terms grew by 1.2%/10.5% QoQ/YoY. Growth was impacted by seasonal softness in the products business (-14.6% QoQ in CC) and ramp down of discretionary spend in Telecom and Tech verticals of ER&D business which declined by 3.8% QoQ. IT business services grew by 0.6% QoQ.
- EBIT margin declined by 140 bps QoQ to 18.2%. 125 bps impact was due to the seasonality in products business; 50 bps impact was due to the ramp down in ER&D business which was negated to the extent of 20 bps by growth in IT services margin.
- TCV of new deal wins was down 8% YoY to \$2,074 mn during the quarter. For FY23, the ACV of order book grew by 4.2%. Total booking for FY23 grew by 19% in FY23.
- Company guided revenue growth for FY24E to be in the range of 6%-8% in CC terms and EBIT margin between 18%-19%. Growth is expected to be driven by volume addition as HCL believes the demand environment is not suitable for price hikes. Tax rate for FY24E is expected to be in the range of 25.5%-26.5% as against 23.8% in FY23. Rise in tax rate is on account of changes in UK tax laws and few units coming out of the SEZ benefit in India. HCL aspires to achieve EBIT margin of 19%-20% in medium term.
- Outlook Discretionary spends are seeing project ramp downs and delayed decision making. Due to the challenging macro conditions, cost take out deals are seeing uptick in demand. In terms of verticals, financial services will remain robust, tech and telecom which are currently observing slowdown are expected to grow on the back of increased cost take out opportunities. In terms of geo, North America remains robust, Europe is seeing healthy pipeline and should be on growth trajectory by Q2FY24E. Moreover, HCL expects the overall recovery to be quicker as its pipeline has reached record high and opportunities in the form of vendor consolidation provide growth opportunities.
- In terms of verticals, manufacturing and technology declined sequentially. Financial services and lifescience recorded growth. HCL alluded that it has gained market share in financial services, retail & CPG, technology and telecommunication. In terms of geo, Americas grew 1.8% in CC while Europe declined by 1.4% in CC.
- Company added 3,674 employees during the quarter; fresher addition stood at 4,480 (i.e. lateral exit of 806). LTM attrition came down to 19.5% v/s 21.7% in previous quarter.



Exhibit 1: Financial snapshot

(Rs mn)

					(,
Year-end: March	Q4FY23	Q3FY23	QoQ (%)	Q4FY22	YoY (%)
Revenues (US\$ mn)	3,235	3,244	(0.3)	2,993	8.1
Revenues	266,060	267,000	(0.4)	225,970	17.7
COGS	173,270	171,350	1.1	146,720	18.1
Gross profit	92,790	95,650	(3.0)	79,250	17.1
SG&A	34,160	32,000	6.7	28,720	18.9
EBITDA	58,630	63,650	(7.9)	50,530	16.0
Depreciation & amortization	10,270	11,370	(9.7)	9,840	4.4
EBIT	48,360	52,280	(7.5)	40,690	18.8
Other income	3,590	1,440	149.3	2,510	43.0
PBT	51,950	53,720	(3.3)	43,200	20.3
Tax	12,140	12,760	(4.9)	7,210	68.4
Minority interest	(20)	0	n.m.	60	n.m.
Reported net profit	39,830	40,960	(2.8)	35,930	10.9
Diluted EPS (Rs)	14.7	15.1	(2.8)	13.3	10.9
As % of net revenue					
Gross profit	34.9	35.8		35.1	
SG&A	12.8	12.0		12.7	
EBITDA	22.0	23.8		22.4	
EBIT	18.2	19.6		18.0	
Reported net profit	15.0	15.3		15.9	
Tax rate	23.4	23.8		16.7	



Exhibit 2: Earnings Revision

		FY24F			FY25E	Y25E		
Year-end: March	New	Old	Chg (%)	New	Old	Chg (%)		
Revenue (US\$ mn)	13,340.5	13,456.7	(0.9)	14,576.2	14868.9	(2.0)		
Revenue (Rs bn)	1,096.6	1,077.9	1.7	1,198.2	1191.0	0.6		
EBIT (Rs bn)	198.7	199.7	(0.5)	219.6	221.4	(0.8)		
EBIT margin (%)	18.12	18.53	(41) bps	18.32	18.59	(26) bps		
EPS (Rs)	56.4	57.4	(1.7)	62.3	63.3	(1.6)		

Exhibit 3: Actual vs. estimates

Year to March	Q4FY22	Q4FY22E	Variance (%)
Revenue (US\$ mn)	3,235	3,217	0.6
Revenue (Rs mn)	266,060	264,561	0.6
EBIT (Rs mn)	48,360	49,177	(1.7)
EBIT margin (%)	18.2%	18.6%	(41)bps
PAT (Rs mn)	39,830	38,269	4.1
PAT margin (%)	15.0%	14.5%	51bps
EPS (Rs)	14.7	14.1	4.1



Exhibit 4: Q4FY23 revenue growth was impacted by ER&D and products business




Exhibit 5: Growth in large clients

Year-end: March	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23
US\$100m +	14	15	15	16	17	17	17	19
US\$50m +	37	41	42	43	42	42	45	46
US\$20m +	104	109	110	118	127	128	130	131
US\$10m +	178	190	198	208	218	220	221	229
US\$5m +	326	329	346	349	353	356	365	375
US\$1m +	817	836	864	882	880	890	937	939



Exhibit 6: Revenue growth across various segments (%)

Parameters	% of revenue	QoQ CC growth	YoY CC growth
Overall revenue growth		1.2	10.5
Geography			
US	63.8	1.8	10.0
Europe	28.9	(1.4)	14.6
ROW	7.3	(1.9)	1.4
Service-lines			
IT and Business services	73.8	1.6	11.4
Engineering and R&D Services	16.1	(3.8)	7.3
Products and Platforms	10.1	(14.6)	8.2
Verticals			
Financial Services	21.2	6.9	9.6
Manufacturing	19.0	(3.5)	11.8
Technology & Services	14.4	(1.6)	11.8
Telecom &Media Publishing	8.8	(5.6)	7.6
Retail & CPG	9.0	0.6	1.6
Life science & Healthcare	17.5	3.6	17.9
Public Services	10.2	-	8.9



Exhibit 7: Q4FY23 EBIT margin declined by 140 bps QoQ






Exhibit 8: SG&A saw a QoQ rise











Financial Summary

Profit & Loss Account (Rs mn)

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Net sales	706,780	753,790	856,510	1,014,560	1,096,587	1,198,167
Change (yoy, %)	17	7	14	18	8	9
Operating expenses	(539,850)	(546,040)	(651,210)	(788,280)	(851,259)	(928,361)
EBITDA	166,930	207,750	205,300	226,280	245,328	269,805
Change (yoy, %)	20	24	-1	10	8	10
Margin (%)	23.6	27.6	24.0	22.3	22.4	22.5
Depreciation	(28,400)	(46,110)	(43,260)	(41,450)	(46,651)	(50,251)
EBIT	138,530	161,640	162,040	184,830	198,677	219,555
Interest paid	-	-	-	-	-	-
Other income	1,790	4,160	7,470	10,050	9,510	10,000
Pre-tax profit	140,320	165,800	169,510	194,880	208,187	229,555
Tax	(30,748)	(36,150)	(34,280)	(46,420)	(54,256)	(59,684)
Effective tax rate (%)	21.9	21.8	20.2	23.8	26.1	26.0
Minority Interest	(320.0)	(240.0)	(240.0)	50.0	(800.0)	(800.0)
Net profit	109,252	129,410	134,990	148,510	153,131	169,070
Exceptional items	-	-	-	-	-	-
Adjusted net profit	109,252	129,410	134,990	148,510	153,131	169,070
Change (yoy, %)	8	18	4	10	3	10
EPS	40.3	47.7	49.7	54.7	56.4	62.3
Dividend per sh	6	26	44	48	45	50
Dividend Payout %	18	55	88	88	80	80



Balar	ce Sheet (Rs m	n)

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Shareholders' funds	512,670	599,130	619,140	654,050	685,006	718,327
Share capital	5,427	5,427	5,430	5,430	5,430	5,430
Reserves & surplus	507,243	593,703	613,710	648,620	679,576	712,897
Total Debt	46,930	38,280	39,230	21,110	21,110	21,110
Other liabilities	25,900	37,200	31,530	32,190	58,175	64,574
Curr Liab & prov	218,850	173,830	187,750	214,310	228,269	249,099
Current liabilities	201,100	151,370	164,820	181,610	195,626	212,941
Provisions	17,750	22,460	22,930	32,700	32,643	36,159
Total liabilities	291,680	249,310	258,510	267,610	307,554	334,784
Total equity & liabilities	805,890	850,130	878,570	921,590	993,290	1,054,641
Net fixed assets	352,420	350,470	329,010	323,220	306,534	286,284
Investments	770	890	1,030	1,100	1,100	1,100
Other non-curr assets	66,700	68,260	68,120	61,500	99,143	108,327
Current assets	386,000	430,510	480,410	535,770	586,512	658,929
Inventories	910	940	1,610	2,280	1,502	1,641
Sundry Debtors	141,310	136,630	154,760	195,720	211,506	231,098
Cash and Bank	119,650	156,610	188,750	201,090	225,774	264,774
Loans and advances	34,220	48,410	30,080	26,030	28,135	30,741
Total assets	805,890	850,130	878,570	921,590	993,290	1,054,641



Cash Flow Statement						(Rs mn)
Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Pre-tax profit	140,320	165,800	169,510	194,880	208,187	229,555
Depreciation	19,000	46,110	43,260	41,450	46,651	50,251
Tax paid	(30,758)	(24,190)	(34,580)	(46,690)	(54,256)	(59,684)
Chg in working capital	57,750	(54,560)	13,450	(11,020)	(3,154)	(1,507)
Other operating activities	(17,980)	27,375	(18,043)	18,830	(20,605)	(13,863)
Cash flow from operations (a)	168,331	160,535	173,597	197,450	182,253	204,751
Capital expenditure	(140,190)	(44,160)	(21,800)	(35,660)	(29,965)	(30,000)
Chg in investments	80	(120)	(140)	(70)	-	-
Other investing activities	-	-	-	-	-	-
Cash flow from investing (b)	(140,110)	(44,280)	(21,940)	(35,730)	(29,965)	(30,000)
Equity raised/(repaid)	2	-	3		-	-
Debt raised/(repaid)	9,920	(8,650)	950	(18,120)	-	-
Dividend (incl. tax)	(19,604)	(70,555)	(119,460)	(130,320)	(122,175)	(135,750)
Chg in monorities	190	(90)	(1,010)	(940)	-	-
Other financing activities	-	-	-	-	-	-
Cash flow from financing (c)	(9,491)	(79,295)	(119,517)	(149,380)	(122,175)	(135,750)
Net chg in cash (a+b+c)	18,730	36,960	32,140	12,340	24,683	39,001



Financial Ratios

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Book Value (Rs)	189	221	228	241	252	265
Adj EPS (Rs)	40.3	47.7	49.7	54.7	56.4	62.3
Adj EPS growth (%)	8	18	4	10	3	10
EBITDA margin (%)	24	28	24	22	22	23
Pre-tax margin (%)	20	22	20	19	19	19
Net Debt/Equity (x)	0	0	0	0	0	0
ROCE (%)	27	26	24	26	27	28
ROE (%)	23.6	23.3	22.2	23.3	22.9	24.1
DuPont Analysis						
Asset turnover (x)	1.0	0.9	1.0	1.1	1.1	1.2
Leverage factor (x)	1.5	1.5	1.4	1.4	1.4	1.5
Net margin (%)	15.5	17.2	15.8	14.6	14.0	14.1
Working Capital & Liquidity ratio						
Inventory days	0	0	1	1	1	1
Receivable days	73	66	66	70	70	70
Payable days	8	12	13	12	12	12

Valuations

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
PER (x)	25.8	21.8	20.9	19.0	18.4	16.7
Price/Book value (x)	5.5	4.7	4.5	4.3	4.1	3.9
EV/Net sales (x)	3.9	3.6	3.1	2.6	2.4	2.1
EV/EBITDA (x)	16	13	13	12	11	10
Dividend Yield (%)	1	3	4	5	4	5





Dealing (91-22) 6836 1111 dealing@idbicapital.com

Key to Ratings Stocks:

BUY: 15%+; **HOLD:** -5% to 15%; **SELL:** -5% and below.

IDBI Capital Markets & Securities Ltd.

Equity Research Desk

6th Floor, IDBI Tower, WTC Complex, Cuffe Parade, Colaba, Mumbai – 400 005. Phones: (91-22) 2217 1700; Fax: (91-22) 2215 1787; Email: info@idbicapital.com

SEBI Registration: BSE & NSE (Cash & FO) - INZ000007237, NSDL - IN-DP-NSDL-12-96, Research - INH000002459, CIN - U65990MH1993GOI075578

Compliance Officer: Christina D'souza; Email: compliance@idbicapital.com; Telephone: (91-22) 2217 1907

Disclaimer

This report has been published by IDBI Capital Markets & Securities Ltd.(hereinafter referred to as "IDBI Capital") for private circulation. This report should not be reproduced or copied or made available to others. No person associated with IDBI Capital is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this report. The information contained herein is strictly confidential and meant for solely for the selected recipient and may not be altered in any way, transmitted to copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without the prior written consent of IDBI Capital.

Recipients may not receive this report at the same time as other recipients, IDBI Capital will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is from the public domain or sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be reliable upon as such. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be reliable upon as such. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Opinions expressed are current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis, the information discussed in this material, IDBI Capital, its directors, employees are under no obligation to update or keep the information current. Further there may be regulatory, compliance, or other reasons that prevent us from doing so.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

IDBI Capital, its directors and employees and any person connected with it, will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report.

This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behavior of investors or recipients or provide any investment/tax advice.

This report is for information only and has not been prepared based on specific investment objectives. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis.

Trading in stocks, stock derivatives, and other securities is inherently risky and the recipient agrees to assume complete and full responsibility for the outcomes of all trading decisions that the recipient makes, including but not limited to loss of capital.

Opinions, projections and estimates in this report solely constitute the current judgment of the author of this report as of the date of this report and do not in any way reflect the views of IDBI Capital, its directors, officers, or employees.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IDBI Capital and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this report may come are required to inform themselves of and to observe such restriction.

E-mail is not a secure method of communication. IDBI Capital cannot accept responsibility for the accuracy or completeness of any e-mail message or any attachment(s).

This transmission could contain viruses, be corrupted, destroyed, incomplete, intercepted, lost or arrived late. IDBI Capital, its directors or employees or associates accept no liability for any damage caused, directly or indirectly, by this email.



Analyst Disclosures

We, Devang Bhatt and Dhawal Doshi, hereby certify that the views expressed in this report accurately reflect our personal views about the subject companies and / or securities. We also certify that no part of our compensation were, are or would be directly or indirectly related to the specific recommendations or views expressed in this report. Principally, We will be responsible for the preparation of this research report and have taken reasonable care to achieve and maintain independence and objectivity in making any recommendations herein.

Other Disclosure

IDBI Capital Markets & Securities Ltd. (herein after referred to as "IDBI Capital") was incorporated in the year 1993 under Companies Act, 1956 and is a wholly owned subsidiary of IDBI Bank Limited. IDBI Capital is one of India's leading securities firm which offers a full suite of products and services to individual, institutional and corporate clients namely Stock broking (Institutional and Retail), Distribution of financial products, Merchant Banking, Corporate Advisory Services, Debt Arranging & Underwriting, Portfolio Manager Services and providing Depository Services. IDBI Capital is a registered trading and clearing member of BSE Ltd. (BSE) and National Stock Exchange of India Limited (NSE). IDBI Capital is also a SEBI registered Merchant Banker, Portfolio Manager and Research Analyst. IDBI Capital is also a SEBI registered depository participant with National Securities Depository Limited (NSDL) and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI).

IDBI Capital and its associates IDBI Bank Ltd. (Holding Company), IDBI Intech Ltd. (Fellow Subsidiary), IDBI Asset Management Ltd. (Fellow Subsidiary) and IDBI Trusteeship Services Ltd. (Fellow Subsidiary).

IDBI Group is a full-serviced banking, integrated investment banking, investment management, brokerage and financing group. Details in respect of which are available on www.idbicapital.com IDBI Capital along with its associates are leading underwriter of securities and participants in virtually all securities trading markets in India. We and our associates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department. Investors should assume that IDBI Capital and/or its associates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material. IDBI Capital generally prohibits its analysts, persons reporting to analysts, and their dependent family members having a financial conflict of interest in the securities or derivatives of any companies that the analysts cover. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Directors of IDBI Capital and or its associates may have interest in the Companies under recommendation in this report either as Director or shareholder. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation or an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of clients of IDBI

IDBI Capital hereby declares that our activities were neither suspended nor we have materially defaulted with any Stock Exchange authority with whom we are registered in last five years. However SEBI, Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time. IDBI Capital, its directors or employees or associates, may from time to time, have positions in, or options on, and buy and sell securities referred to herein. IDBI Capital or its associates, during the normal course of business, from time to time, may solicit from or perform investment banking or other services for any company mentioned in this document or their connected persons or be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or their affiliate companies or act as advisor or lender / borrower to such company(ies)/associates, companies or have other potential conflict of interest. This report may provide hyperlinks to other websites. Except to the extent to which the report refers to the website of IDBI Capital, IDBI Capital states that it has not reviewed the linked site and takes no responsibility for the content contained in such other websites. Accessing such websites shall be at recipient's own risk. IDBI Capital encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. Accordingly, neither IDBI Capital nor Research Analysts have any material conflict of interest at the time of publication of this report. We offer our research services to primarily institutional investors and their employees, directors, fund managers, advisors who are registered with us. The Research Analyst has not served as an officer, director or employee of Subject Company. We or our associates may have received compensation for investment banking o